본문 바로가기

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1
저널
ANNALS OF ONCOLOGY21(1) · pp.140 · 2010
피인용
Web of Science 52
JCR IF
JCR 2009 5.647
ISSN
0923-7534

저자

  1. 송무곤제1저자부산대학교, 의과대학, 의학과, KO
  2. 정주섭교신저자부산대학교, 의과대학, 의과학과, KO
  3. 설영미부산대학교, 의과대학, 의학과, KO
  4. 김성근부산대학교, 부산대학교병원, 대학병원, KO
  5. 신호진부산대학교, 의과대학, 의학과, KO
  6. 최영진부산대학교, 의과대학, 의학과, KO
  7. 조군제부산대학교, 의과대학, 의학과, KO
  8. 신동훈부산대학교, 의과대학, 의학과, KO

초록

Patients and methods: One hundred and thirty-six DLBCL patients who were treated with R-CHOP from 2003 to 2007 were analyzed in the present study. Results: ALC >= 1.0 x 10(9)/l predicted a longer 3-year progression-free survival (PFS) and 3-year overall survival (OS) versus ALC < 1.0 x 10(9)/l (82.6% versus 60.0%, P = 0.005 and 87.2% versus 62.0%, P < 0.001, respectively). Non-GC type had similar PFS and OS to germinal center type (68.2% versus 80.0%, P = 0.074 and 72.7% versus 82.9%, P = 0.111, respectively). However, considering clinical influence of the ALC according to immunophenotype, low ALC in non-GC type DLBCL was associated with lower PFS and OS compared with others (PFS, P = 0.002; OS, P < 0.001). Multivariate analysis revealed that low ALC in non-GC type had lower PFS [hazard ratio (HR) = 3.324, P = 0.001] and OS (HR = 4.318, P < 0.001), independent of international prognostic index. Conclusion: A low ALC in non-GC type DLBCL counteracted the beneficial effect of rituximab on survival.

식별자

WoS UID
000272924300023